J. Rey

发表

NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML

D. Olive, D. Blaise, A. Toubert, 2017, Oncoimmunology.

Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients.

D. Blaise, Wang LiNing, R. Devillier, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.

P. Cony-Makhoul, V. Ugo, E. Lippert, 2021, Blood advances.

Natural killer and gammadelta T cells in haematological malignancies: enhancing the immune effectors.

R. Bouabdallah, D. Olive, J. Rey, 2009, Trends in molecular medicine.

Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms

F. Pasquier, E. Solary, W. Vainchenker, 2020, Oncogene.

A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies

G. Salles, D. Berton‐Rigaud, J. Rey, 2018, Oncotarget.

New approaches in the immunotherapy of haematological malignancies

D. Olive, C. Fauriat, J. Rey, 2003, European journal of haematology.

[Primary mediastinal B-cell lymphoma].

R. Bouabdallah, D. Coso, J. Rey, 2010, Revue de pneumologie clinique.

Epidemiology, clinical picture and long‐term outcomes of FIP1L1‐PDGFRA‐positive myeloid neoplasm with eosinophilia: Data from 151 patients

J. Cayuela, P. Cony-Makhoul, C. Preudhomme, 2020, American journal of hematology.

Vasculitis associated with large granular lymphocyte (LGL) leukemia: presentation and treatment outcomes of 11 cases.

E. Lazaro, J. Rey, N. Schleinitz, 2013, Seminars in arthritis and rheumatism.

The co‐expression of 2B4 (CD244) and CD160 delineates a subpopulation of human CD8+ T cells with a potent CD160‐mediated cytolytic effector function

D. Olive, J. Rey, F. Mallet, 2006, European journal of immunology.

Natural Killer Cell-triggering Receptors in Patients with Acute Leukaemia

D. Olive, C. Fauriat, J. Rey, 2003, Leukemia & lymphoma.

Immunobiology of haematological malignant disorders: the basis for novel immunotherapy protocols.

D. Olive, C. Fauriat, J. Rey, 2004, The Lancet. Oncology.

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study

P. Cony-Makhoul, L. Knoops, V. Ugo, 2017, Haematologica.

Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase

D. Birnbaum, R. Devillier, J. Rey, 2014, Haematologica.

Efficacy and safety of pegylated‐interferon α‐2a in myelofibrosis: a study by the FIM and GEM French cooperative groups

P. Cony-Makhoul, L. Knoops, K. Laribi, 2013, British journal of haematology.

A role for HVEM, but not lymphotoxin‐β receptor, in LIGHT‐induced tumor cell death and chemokine production

D. Olive, A. Bernard, J. Rey, 2009, European journal of immunology.

Targeted molecular characterization shows differences between primary and secondary myelofibrosis

D. Birnbaum, V. Ugo, F. Delhommeau, 2020, Genes, chromosomes & cancer.

Mutation patterns in essential thrombocythemia, polycythemia vera and secondary myelofibrosis

D. Birnbaum, J. Rey, N. Vey, 2019, Leukemia & lymphoma.

A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma

R. Bouabdallah, L. Xerri, B. Chetaille, 2006, Bone Marrow Transplantation.

Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms

D. Birnbaum, J. Rey, N. Vey, 2018, American journal of hematology.

Intensive chemotherapy with rituximab is safe and effective in AIDS non-Hodgkin's lymphoma.

J. Rey, I. Poizot-Martin, R. Costello, 2003, AIDS.

“One Hour” Rituximab Infusion Is Safe and Improves Patient Care and Outpatient Unit Management.

R. Bouabdallah, D. Coso, J. Rey, 2005 .

Comparison of 60 or 90 mg/m2 of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics

D. Blaise, C. Récher, R. Devillier, 2015, American journal of hematology.

Prognostic significance of myelodysplasia‐related changes according to the WHO classification among ELN‐intermediate‐risk AML patients

D. Blaise, R. Devillier, J. Rey, 2015, American journal of hematology.

Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction

D. Blaise, J. Rey, C. Arnoulet, 2012, Leukemia & lymphoma.

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients

J. Rey, N. Vey, V. Maisano, 2022, Cancers.

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo

C. Klade, R. Kralovics, H. Gisslinger, 2018, Blood Cancer Journal.

PEG‐IFN‐α‐2a therapy in patients with myelofibrosis

J. Rey, J. Abgrall, L. Roy, 2009 .

Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy.

D. Blaise, J. Rey, N. Vey, 2017, Clinical lymphoma, myeloma & leukemia.

Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France

J. Viallard, J. Rey, J. Kiladjian, 2013, European journal of haematology.

Early ICU Admission Of Newly Diagnosed Acute Myeloid Leukemia With No Organ Failure

C. Récher, J. Rey, N. Vey, 2013 .

Impact of CRi on the Outcome of Elderly Patients with Untreated Acute Myeloid Leukemia (AML)

D. Coso, J. Rey, N. Vey, 2008 .

Detection of different clonal EBV strains in Hodgkin lymphoma and nasopharyngeal carcinoma tissues from the same patient

R. Bouabdallah, P. Brousset, L. Xerri, 2008, British journal of haematology.

Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome

D. Blaise, J. Rey, N. Vey, 2020, Annals of Hematology.

JC papovavirus leukoencephalopathy after first line treatment with CHOP and rituximab

R. Bouabdallah, D. Coso, J. Rey, 2007, Haematologica.

Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms

F. Bertucci, D. Birnbaum, P. Finetti, 2012, Genes, chromosomes & cancer.

Concomitant germ‐line RUNX1 and acquired ASXL1 mutations in a T‐cell acute lymphoblastic leukemia

D. Birnbaum, W. Vainchenker, R. Favier, 2013, European journal of haematology.

Natural killer cells in leukaemia

D. Olive, C. Fauriat, J. Rey, 2010 .

Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast‐phase myeloproliferative neoplasms

H. Dombret, M. Robin, T. Cluzeau, 2016, British journal of haematology.

Genomic analysis of myeloproliferative neoplasms in chronic and acute phases

D. Birnbaum, N. Cervera, J. Rey, 2017, Haematologica.

Primary B-CLL Resistance to NK Cell Cytotoxicity can be Overcome In Vitro and In Vivo by Priming NK Cells and Monoclonal Antibody Therapy

R. Bouabdallah, D. Olive, D. Coso, 2012, Journal of Clinical Immunology.

Long Lasting Alteration of Natural Killer Cells Post-Chemotherapy in Elderly Patients with Acute Myeloid Leukemia (AML).

D. Olive, F. Orlanducci, J. Rey, 2009 .

Poor autologous mobilization status does not impact on hematological recovery but affects outcome after allogeneic stem cell transplant for lymphoma and myeloma

R. Bouabdallah, B. Esterni, D. Blaise, 2013, Leukemia and Lymphoma.

HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison.

D. Blaise, R. Devillier, S. Harbi, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.

D. Blaise, R. Devillier, S. Harbi, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases

T. Fest, O. Reman, J. Rey, 2010, Haematologica.

Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia

S. Granjeaud, D. Olive, A. Toubert, 2017, Front. Immunol..

A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL).

G. Salles, D. Berton‐Rigaud, J. Rey, 2015 .

Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.

R. Bouabdallah, D. Blaise, C. Oudin, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

IDH Mutations Identify a Subgroup of NPM1 Patients with a More Favorable Prognosis. a Retrospective Multicenter Study of the Filo Group

M. Béné, C. Récher, J. Rey, 2020 .

Granular lymphoproliferative disorder, autologous blood stem cell transplantation and multiple myeloma

D. Olive, J. Rey, R. Costello, 2003, European journal of haematology.

Kinetics of Cytotoxic Lymphocytes Reconstitution after Induction Chemotherapy in Elderly AML Patients Reveals Progressive Recovery of Normal Phenotypic and Functional Features in NK Cells

D. Olive, C. Fauriat, F. Orlanducci, 2017, Front. Immunol..

Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia

D. Blaise, R. Devillier, J. Rey, 2013, Leukemia & lymphoma.

Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia

C. Récher, J. Rey, N. Vey, 2017, Leukemia & lymphoma.

Socioeconomic deprivation is associated with decreased survival in patients with acute myeloid leukemia.

J. Rey, J. Boher, A. Charbonnier, 2020, Cancer epidemiology.